Navigation Links
Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment
Date:9/23/2009

NEW YORK, Sept. 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation has committed up to $5 million for research to successfully translate neurotrophic factor advances from pre-clinical and early-phase clinical work into a practical, patient-relevant treatment for Parkinson's disease. The funding will be awarded under a new Directed LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) initiative.

The Foundation's intention is to identify and drive ambitious projects with a clear plan for accelerating trophic factor therapy through the stages of preclinical and clinical development up to and including Phase 2 clinical studies. Also of interest are therapeutic approaches that include evidence that the trophic factor being studied holds potential for neuroregeneration (helping the brain rejuvenate sick cells) and not merely neuroprotection (protecting existing neurons from death).

Neurotrophic factors (also known as trophic factors or growth factors) are specialized proteins that protect and nourish neurons in the brain, including the dopamine neurons that die in Parkinson's disease. They are a high-priority therapeutic target for MJFF, which has committed approximately $20 million to their development to date, because they have shown potential to slow or stop the progression of Parkinson's in the brain -- something no currently available treatment has been proven to do.

In the last several years, preclinical studies and several early-phase clinical trials in neurotrophic factors have shown promise to revolutionize the treatment of PD. Research increasingly indicates that trophics are safe for use in people, and several Phase 1 neurotrophic clinical trials have shown signs of efficacy. But results from all previous trials have been ultimately inconclusive, and no trophic-based approach has yet been demonstrated to be both safe and efficacious in a Phase 2 clinical trial.

"While many unanswered questions remain about the potential of neurotrophic factors as therapies for PD, MJFF continues to regard neurotrophic factor therapy as a promising avenue," said Todd Sherer, PhD, vice president of research programs at MJFF. "We believe the approach deserves additional rigorous investigation in hope of advancing the field from promise to reality -- or at least definitively determining its viability."

This Directed LEAPS program is open to academic and industry researchers. Pre-proposals are due November 18, 2009. Funding is anticipated in June 2010. The full RFA and detailed information on submitting an application are available at www.michaeljfox.org/research.


The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded $149 million in research to date.

    Media contact:
    Holly Barkhymer
    212-509-0995 x242
    hbarkhymer@michaeljfox.org

    Research contact:
    Jamie Eberling, PhD
    212-509-0995 x278
    jeberling@michaeljfox.org
     


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Myers Jackson ... his has the ability to sell luxury homes anywhere on the planet. The luxury ... county side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill ...
(Date:5/24/2017)... Soquel, California (PRWEB) , ... May 24, 2017 , ... If you are thinking of ... you are interested in business architecture, October is the perfect time to visit. , Business ... as an à la carte offering for individuals, as a 4-½ day package for individuals, ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... YORK, NY (PRWEB) , ... May 23, 2017 ... ... makers in the pharmaceutical and medical device sectors, today announced the winners of ... Transformers • Entrepreneurs) represent the most influential people in the healthcare industry today. ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, ... this month as a Guest Speaker and Contributor to a weeklong series of classes, ... Purpose. , Walter Schindler and SAIL Capital have received ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... May 4, 2017  Fortuna Fix Inc. (" Fortuna ... the first to eliminate the need for embryonic and fetal ... treat neurodegenerative diseases. Fortuna announced today ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald ... MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... announced that it is teaming up with Auto Control ... lower diabetes healthcare costs in Canada ... available throughout all provinces and territories in ... additional savings when shopping for Dario supplies in local ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information notes ... nine percent next year and this is projected ... hematopoietic stem cell (HSCT) or bone marrow transplants ... technologies are well-suited for this task. This according ... publisher Kalorama Information. The various PCR-based methodologies, Sanger ...
Breaking Medicine Technology: